Gencove

Gencove

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.8M

Overview

Founded in 2015, Gencove has developed a proprietary low-pass sequencing platform that offers a cost-effective alternative to traditional genotyping microarrays, enabling scalable whole-genome analysis. The company operates a dual business model, serving enterprise research and pharmaceutical partners while also marketing a direct-to-consumer health product. Its technology is positioned to become a standard in research and diagnostics by providing more comprehensive genetic data that supports reanalysis as science evolves.

Genetics & GenomicsDiagnostics

Technology Platform

Low-pass whole genome sequencing (LP-WGS) and bioinformatics platform for generating polygenic risk scores and genomic insights across species.

Funding History

3
Total raised:$12.8M
Series A$10M
Grant$330K
Seed$2.5M

Opportunities

Expansion of polygenic risk score applications in preventive healthcare and integration with digital health ecosystems (wearables, labs).
International rollout of the DTC product and growth in enterprise research contracts, particularly in pharmacogenomics and agricultural genomics.

Risk Factors

Regulatory uncertainty for DTC genetic health reports, intense competition in consumer genetics, and scientific communication challenges around the probabilistic nature of polygenic risk scores.
Balancing resources between enterprise and consumer business models also presents an execution risk.

Competitive Landscape

Competes with DTC giants (23andMe, AncestryDNA) using microarrays, and with other sequencing-based services (Nebula Genomics, Dante Labs). In the enterprise space, competes with genotyping array providers (Illumina, Thermo Fisher) and other low-pass sequencing analytic firms. Differentiation hinges on the cost-effectiveness and data richness of its low-pass sequencing platform.